We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LSEG:LSELondon Stock Exchange Group plc Analysis

Data as of 2026-05-20 - not real-time

£9,372.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

LSEG delivered record Q1 revenue up 9.8% beating consensus, driven by double‑digit growth in Markets and Risk Intelligence segments. Price sits at 9,372 £, well above the 20‑day SMA (9,462) and 50‑day SMA (9,089) but still below the 200‑day SMA (8,836), indicating a bullish short‑term trend despite a bearish MACD histogram (‑33.9) and a neutral RSI (52.6).
Valuation metrics show the stock trades at a trailing P/E of 39.5× versus an industry average of 16.7×, placing it in the overvalued tier, while the forward P/E of 17.5× suggests expected earnings acceleration. The upside/downside indicator of +31.7 % further underscores market optimism, yet the fear‑greed index at 90.3 (Extreme Greed) flags potential sentiment‑driven volatility.
Risk factors are mixed: 30‑day volatility of 25 % is high, beta is effectively neutral (‑0.04) limiting systematic market risk, and the financial‑services sector carries medium‑to‑high regulatory exposure. Liquidity appears solid with stable volume and a market cap of £45.96 bn, while dividend yield of 1.59 % and a payout ratio of 57 % are supported by robust operating cash flow (£3.62 bn) and free cash flow (£2.05 bn).
Overall, the combination of strong cash generation, record‑breaking revenue growth, and a sizable upside potential makes the stock attractive for investors with a short‑to‑medium horizon, but the elevated valuation and sector‑specific regulatory risk counsel caution for long‑term holders.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 8/10

Key Factors

  • record Q1 revenue growth
  • price above SMA20 and bullish short‑term trend
  • MACD bearish histogram suggests near‑term pullback opportunity

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • forward P/E compression to 17.5×
  • double‑digit segment growth expected to continue
  • stable dividend yield and strong cash generation

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • trailing P/E of 39.5× versus industry average of 16.7×
  • high regulatory exposure in financial‑services sector
  • valuation compression risk may limit upside over time

Key Metrics & Analysis

Financial Health

Revenue Growth4.60%
Profit Margin13.36%
P/E Ratio39.5
ROE6.37%
ROA0.19%
Debt/Equity52.97
P/B Ratio2.4
Op. Cash Flow£3.6B
Free Cash Flow£2.1B
Industry P/E16.7

Technical Analysis

TrendBullish
RSI52.6
Support£8,196.00
Resistance£10,140.00
MA 20£9,462.80
MA 50£9,088.12
MA 200£8,835.69
MACDBearish
VolumeStable
Fear & Greed Index90.3

Valuation

Fair Value£5,039.10
Target Price£12,346.35
Upside/Downside31.74%
GradeOvervalued
TypeBlend
Dividend Yield1.59%

Risk Assessment

Beta-0.04
Volatility25.15%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.